AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Savara Plunges 31.69% on FDA Rejection of MOLBREEVI
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, May 27, 2025 8:26 am ET1min read
On May 27, 2025, Savara's stock experienced a significant drop of 31.69% in pre-market trading, marking a substantial decline in its share price.
Savara Inc. received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) for MOLBREEVI. This decision by the FDA has raised concerns among investors about the future prospects of the company's flagship product.
In response to the RTF letter, Savara's management has stated that the requested Chemistry, Manufacturing, and Controls (CMC) data are currently being generated. The company is looking forward to meeting with the FDA to align on the next steps, indicating a proactive approach to addressing the regulatory hurdles.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Serve Robotics Surges 5.16% as Trump Admin Boosts Robotics Push, Eyes 10X Revenue by 2026
Dec.12 2025
New Pacific Metals (NPM) Soars 7.98% as Base Metals Market Anticipates Supply/Demand Shifts
Dec.12 2025
Gevo Inc. (GEVO) Surges 6.22% on $26M BioRecro Partnership to Expand Carbon Management Capabilities
Dec.12 2025
Sable Offshore Soars 5.82% as Private Placement and Policy Tailwinds Drive Pre-Market Rally
Dec.12 2025
Mastercard Inc. Surges 4.55% as Fintech Optimism and AI Expansion Drive Pre-Market Rally
Dec.12 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet